Atrasentan · Vanrafia

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: IgA Nephropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

The proteinuria result supported accelerated approval. The confirmatory eGFR comparison at week 136 was not statistically significant (2.39 mL/min/1.73m2 vs placebo, 2-sided p=0.057; Novartis, 13 February 2026).

track record: Partial signal

Also approved (1)
CN
  • Reduction of proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression (accelerated/conditional approval; Chinese brand Nuoruida)
Product first approved 2025pharnexcloud.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (9)
IgA Nephropathy
NCT07498335 · Novartis Pharmaceuticals
2026-08-06 – 2032-12-13 · Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type
What this study did
NCT07850752 · Novartis Pharmaceuticals
2026-11-11 – 2030-12-25 · IgA Nephropathy (IgAN)
What this study did
Other / comorbidity
NCT01858532 · AbbVie
Run by former owner AbbVie
2013-05-17 – 2018-03-29 · Diabetic Nephropathy
What this study did
NCT00134056 · SWOG Cancer Research Network
2006-08 – 2016-02 · Metastatic Cancer, Prostate Cancer
What this study did
NCT00271492 · Mayo Clinic
2001-07 – 2008-01 · Endothelial Dysfunction
What this study did
NCT00036556 · Abbott
started 2001-06 · Prostatic Neoplasms
What this study did
NCT00046943 · Abbott
2002-09 – 2007-06 · Prostate Cancer
What this study did
NCT00036543 · Abbott
started 2001-05 · Prostate Cancer
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT00127478 · Abbott
2001-07 – 2007-06 · Prostate Cancer, Adenocarcinoma
What this study did
Phase 2 (11)
IgA Nephropathy
NCT04573920 · Novartis Pharmaceuticals
2021-03-15 – 2026-10-27 · IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
What this study did
NCT05834738 · Novartis Pharmaceuticals
2023-07-20 – 2025-10-29 · IgA Nephropathy, Immunoglobulin A Nephropathy
What this study did
Other / comorbidity
NCT02118714 · AbbVie
Run by former owner AbbVie
2015-04-06 – 2018-07-16 · Nephropathy, Diabetes
What this study did
NCT01399580 · AbbVie (prior sponsor, Abbott)
Run by former owner AbbVie
2011-08 – 2012-09 · Chronic Kidney Disease, Diabetic Nephropathy
What this study did
NCT01424319 · AbbVie (prior sponsor, Abbott)
Run by former owner AbbVie
2011-08 – 2012-07 · Chronic Kidney Disease, Diabetic Nephropathy
What this study did
NCT00920764 · AbbVie (prior sponsor, Abbott)
Run by former owner AbbVie
2009-06 – 2010-05 · Chronic Kidney Disease, Diabetic Nephropathy
What this study did
NCT00653328 · Vanderbilt-Ingram Cancer Center
2003-05 – 2009-03 · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
What this study did
NCT00181558 · Massachusetts General Hospital
2001-12 – 2006-12 · Prostate Cancer, Adenocarcinoma of the Prostate
What this study did
NCT00038662 · Abbott
started 2002-05 · Prostatic Neoplasms
What this study did
NCT00039429 · Eastern Cooperative Oncology Group
2003-07-14 – 2006-04 · Kidney Cancer
What this study did
Phase 1 (1)
Other / comorbidity
NCT00017264 · National Cancer Institute (NCI)
started 2002-06 · Brain and Central Nervous System Tumors
What this study did
Phase 4 (1)
IgA Nephropathy
NCT07820995 · University of Illinois at Chicago
2026-09-29 – 2028-12-31 · IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for IgA Nephropathy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Atrasentan (Vanrafia): this drugApprovedSmall moleculeEndothelin A receptorPartial signal
NCT04573478: Primary (interim, first 270 patients): 24-hour UPCR change at week 36, atrasentan -38.1% vs placebo -3.1%; between-group difference -36.1 percentage points (95% CI -44.6 to -26.4), P<0.001
Ambrisentan (Letairis)
Approved(overall)
Small moleculeEndothelin A receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
AtaciceptApprovedProtein / enzyme therapeuticBLyS/APRIL (B-cell activating factor/a proliferation-inducing ligand)Partial signalFeatured results are non-efficacy only in this race
Budesonide (targeted-Release) (TARPEYO / Nefecon)ApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Iptacopan (Fabhalta)ApprovedSmall moleculeComplement Factor BPartial signal
NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met.
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5Partial signal
NCT06291376: Primary 1, change in 24-hour UPCR at week 34 (prespecified interim analysis), ravulizumab vs placebo: the sponsor reports a statistically significant and clinically meaningful reduction, met; figures not yet published. Primary 2, change in eGFR at week 106: not yet reported; the trial is ongoing.
Sparsentan (Filspari)ApprovedSmall moleculeAngiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Partial signalFeatured results are non-efficacy only in this race
FelzartamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
JADE101Phase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
MezagitamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
PovetaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
SefaxersenPhase 3RNA / oligonucleotideComplement factor B (CFB)Partial signal
NCT05797610: Prespecified interim analysis: statistically significant reduction in proteinuria (24-hour UPCR) vs placebo at week 37 (2026-09-23).
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
Zibotentan + Dapagliflozin
Phase 3(overall)
Small moleculeEndothelin A receptor, SGLT2
not yet graded(overall)
No reviewed efficacy summary in this indication
ZigakibartPhase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
Ebribafusp AlfaPhase 2Protein / enzyme therapeuticC3d / Factor Hnot yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 1/2Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
ARO-CFBPhase 1RNA / oligonucleotideComplement factor B (CFB) mRNAnot yet gradedNo reviewed efficacy summary in this indication
Opemalirsen
Phase 1(overall)
RNA / oligonucleotide—not yet gradedNo reviewed efficacy summary in this indication
F230
—(overall)
Small moleculeEndothelin A receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Vanrafia (Atrasentan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 4IgA NephropathyNot yet recruiting
Est. primary completion 2027-12-31 · NCT07820995 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
Phase 3IgA NephropathyActive not recruiting
Est. primary completion 2028-04-14 · NCT04573478 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3IgA NephropathyRecruiting
Est. primary completion 2028-09-17 · NCT07850752 · CT.gov ↗
What to watch
2031 (1)
September 2031 (1)
Phase 3IgA NephropathyRecruiting
Est. primary completion 2031-09-15 · NCT07498335 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 February 2026Topline resultALIGN Phase III final eGFR results